AzTrials
AzTrials

Overweight and ObesityNCT03812211

Evaluation of a Supplement for Weight Management in Obese and Overweight Individuals

A study testing Active Supplement in people with Overweight and Obesity and Men, run by McMaster University at 1 site in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this trial is to examine the effects of a novel, orally consumed dietary supplement (composed of naturally occurring components) on weight management and metabolic rate in individuals who are overweight or obese following a 12-week supplementation period. Read more about this study

Who is it for?
Ages 18 to 55 yearsHealthy volunteers can take part
Conditions the study is for
Overweight and Obesity, Men, Women
What is being tested?
Active Supplement
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
65 participants
Where
1 siteCanada
Study dates
1 Mar 2019to 2 Dec 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Male or female
  • overweight (BMI 25 - 29.9 kg/m2) or obese (BMI > 30 kg/m2)
  • Physically inactive (< 1 hour of formal exercise/week)

Who cannot join

  • Participants will be excluded and/or released from the study if they meet any one of the following:
  • Smoking
  • Use of assistive walking devices (e.g., cane, or walker)
  • Chronic use of analgesic or anti-inflammatory drugs
  • Diabetes mellitus (more than one anti-diabetic drug)
  • Cardiovascular disease (recent myocardial infarction (< 6 months) and/or hypertension requiring more than 2 medications)
Show all 18Show fewer
  • Congestive heart failure requiring more than one medication for control
  • Renal disease (creatinine > 140)
  • Previous stroke
  • Active musculoskeletal injuries and/or severe osteoarthritis
  • Significant weight loss in the 3-month period prior to the study
  • Vegan diet
  • Muscular dystrophy
  • Severe peripheral neuropathy
  • Severe osteoporosis
  • Use medications known to affect protein metabolism (i.e. corticosteroids)
  • Inability to consent
  • Chronic obstructive pulmonary disease, and asthma requiring more than two medications.

Trial locations and contacts

1 site in 1 country.

Canada1 site
  • McMaster University Medical Center

    Hamilton, Ontario, L8N 3Z5

Other trials in Canada

About this study

The purpose of this trial is to examine the effects of a novel, orally consumed dietary supplement (composed of naturally occurring components) on weight management and metabolic rate in individuals who are overweight or obese following a 12-week supplementation period. The investigator's primary outcome will be changes in body composition measured via dual energy x-ray absorptiometry (DXA), which will measure changes in fat and lean mass during the supplementation period. Another primary objective will be to determine whether or not the body mass index (BMI) changes during the supplementation period. A secondary objective of the study is to determine whether anthropometric measurements (waist-to-hip ratio) is altered following the supplementation period. Another secondary objective of this study is to determine whether metabolic rate (as measured in VO2 consumption at rest and during exercise) is changed following the supplementation period. Another secondary objective is to determine whether blood pressure (systolic and diastolic pressure, measured in mm Hg) and physical function (measured via VO2peak in mL/min/kg-1 and leg strength in kilograms) change when the supplement is administered over a 12-week period. Another secondary objective will determine how glycemic control, blood markers of inflammation and cholesterol are affected by this intervention.

Read the detailed description

The present study is a randomized double-blind placebo controlled repeated measures design, with sampling of the cohorts on five separate occasions.

Group 1: Intervention Group (n = 24) Healthy, overweight or obese physically inactive males, supplement, n = 12 Healthy, overweight or obese physically inactive females, supplement, n=12 Group 2: Placebo Group (n = 24) Healthy, overweight or obese physically inactive males, no supplement, n = 12 Healthy, overweight or obese physically inactive females, no supplement, n=12

Participants will be asked to make 5 visits.

Day 0 (Visit 1): Eligible participants that provided informed consent will complete a medical screening questionnaire to determine their readiness to perform exercise. Participants will thus complete the SF-36 and CSEP Get Active Questionnaire form. Participant characteristics will then be measured. At this time, anthropometric measurements (i.e., height, weight, waist circumference) and a dual energy x-ray absorptiometry (DXA) measurement will be performed. This must be done in order to verify that the participant meets the inclusion criteria of being overweight. Following this screening, participants will begin the following the study timeline.Upon completion, participants will be randomized into one of two groups.

Day 1 (Visit 2): Participants will arrive following an overnight fast (including no caffeine for 12 hours) and having abstained from any exercise for the prior 48 hours. Participants will enter the clinic, and rest quietly in the supine position for 25 minutes before having blood pressure with a non-invasive automated cuff and resting metabolic rate via metabolic cart measured. Following resting blood pressure and baseline metabolic rate assessment, blood will be drawn from an antecubital vein. Thereafter, functional metrics will be determined including strength (both upper and lower body muscles; and aerobic capacity (V02peak). Following testing, participants will be provided with a 3-day diet log (which will be completed every two weeks) and a pedometer.

Day 14 (Visit 3); Participants will arrive following an overnight fast (including no caffeine for 12 hours) and having abstained from any exercise for the prior 24 hours. Participants will undergo a DXA. Blood will be drawn from an antecubital vein.

Day 49 (Visit 4); Participants will arrive following an overnight fast (including no caffeine for 12 hours) and having abstained from any exercise for the prior 24 hours. Participants will undergo a DXA.

Follow-up - Day 7, 21, 28, 35, 42, 56, 63, 70, 77: Participants will receive a weekly phone call to determine their pedometer counts for the week, and to ensure that participants are adhering to the supplement consumption, and to address any concerns.

Day 84 (Visit 5); Participants will repeat Day 1 (automated blood pressure, resting and maximal metabolic rate, blood draw, functional metrics. Participants will return their pedometer and remuneration will be processed.

Study products (active supplement vs. placebo) will be provided in a blinded fashion by Infinit Nutrition Canada (Windsor, Ontario). The active supplement is composed of vitamins, minerals and naturally occurring and plant extracts approved for consumption. Participants will be asked to consume 3 servings of the study product per day (7 days per week) throughout the 12-wk intervention period. Participants will consume 1 serving immediately before breakfast. Participants will be instructed to consume the supplement in a single sitting, with water, within 5-10 min. Participants will be instructed to record product intake in a diary to check compliance. Participants will also be asked to maintain the used package and turn it in at the check-ins as a marker of study compliance. To maintain the double-blind nature of the experiment, the placebo, which contains microcrystalline cellulose, will be matched in size, appearance, taste and caloric value

Three day weighed food record. Participants will be asked to record everything that they consumed for 3 non-consecutive days: 2 week-days and either a Saturday or a Sunday. On completion of the food record, it will be analyzed using a commercially available computerized database software (Nutribase version 11.5, Cybersoft Inc., Phoenix, AZ, USA). Food items will be aggregated into the following categories: fruit (e.g., fresh/frozen, tinned, juice), vegetables (e.g., fresh/frozen, canned), dairy products (e.g., milk, yoghurt, cheese), breads and cereals (e.g., bread, breakfast cereal, rice, pasta), meats and alternatives (e.g., red meat, poultry, fish, pork, processed meat, tofu, eggs, nuts) and extra foods (e.g., hamburger, pizza, meat pies, chocolate, cake, ice cream, jam, biscuits, crackers, crisps, alcohol etc.).

Resting metabolic rate (RMR). Participants will be asked to lay still on a bed will connected to a metabolic cart with an on-line gas collection system (Moxus modular oxygen uptake system, AEI Technologies, Pittsburgh, PA), and the system will acquire oxygen consumption (VO2) and carbon dioxide (CO2) production data for 15 minutes.

Blood sampling. A total of ~16 mL blood per visit will be taken from the antecubital vein and drawn into evacuated tubes with heparin used for plasma collection and non-treated tubes will be used to collect serum. Blood sampling will be used for the following panel of tests: complete blood count (CBC), glucose, Gamma-Glutamyl Transferase (GGT), bilirubin, Alanine Aminotransferase (ALT), creatine kinase (CK), creatinine, triglycerides, total cholesterol, LDL and HDL, insulin, CRP, and leptin.

Maximal voluntary VO2peak fitness test. Participants will complete double-leg incremental peak oxygen uptake (VO2peak) tests on a cycle ergometer (Lode, Groningen, the Netherlands). A metabolic cart with an on-line gas collection system (Moxus modular oxygen uptake system, AEI Technologies, Pittsburgh, PA) will acquire oxygen consumption (VO2) and carbon dioxide (CO2) production data. For double-leg cycling, the test will begin with a 1-min warm up at 50 watts (W), after which the power will be increased by 1 W every two seconds until volitional exhaustion or the point at which pedal cadence falls below 60 rpm. Heart rate will be monitored continuously throughout the test via telemetry with a heart rate monitor (Polar A3, Lake Success, NY). VO2peak will be defined as the highest oxygen consumption achieved over a 30-s period. Maximal workload (Wmax) will be the highest power output achieved during the test. After the completion of the test, the participant will be asked to perform a 2-3-minute active recovery pedaling against no resistance.

Pedometer. Participants will be given a wearable activity tracker (pedometer). All participants will record their daily totals for subsequent analysis.

Dual X-ray absorptiometry (DXA) and blood pressure. A DXA scan is a non-invasive procedure requiring the participant to only lay still on a padded table. It is a fast procedure that provides a variety of body composition variables (bone mass/area/density, fat mass, and fat free mass). The DXA scan exposes individuals to low levels of radiation, approximately 0.18 millirem. According to the United States Nuclear Regulatory Commission, Americans receive approximately 620 millirem each year, half of which is due to environmental background radiation. Radiation exposure can be due to medical treatments or procedures, like X-Ray or MRI's, food, sun exposure, etc. Any exposure to radiation can increase the risk of cancer. In the present study, body composition will be assessed using DXA scan (GE Lunar Prodigy, Madison, WI) and a software program for adults (encore Version 9.15.010). Fat free mass (FFM), fat mass (FM) and bone mineral density (BMD) of the entire body will be recorded. Arterial blood pressure (i.e., systolic [SBP] and diastolic [DBP]) will be measured during rest with a stethoscope (Marshall Nurse Stethoscope, Riverside, Ill., USA) and sphygmomanometer (MDF Instruments Direct Inc., Agoura Hills, Calif., USA).

Waist and hip circumference measures. For waist circumference measurement, the participant will stand with arms at the sides, feet together, and abdomen relaxed. Using a Gulick tape measure, a horizontal measure will be taken at the narrowest part of the torso (above the umbilicus and below the xiphoid process). Obtaining a horizontal measure directly above the iliac crest enhances standardization according to The National Obesity Task Force. For hip circumference measurement, the participant stands erect and feet together, a horizontal measure is taken at the maximal circumference of buttocks.

Leg press 1RM. Assessment procedures for determining lower body strength using leg press exercise equipment (Cybex Eagle ®, Medway, MA) will require the participant to sit in the leg press machine with the right foot and left foot on the weight platform. The seat and back pad will be adjusted so that feet are flat on the platform hip-width apart, toes slightly angled out, and legs parallel to each other. The interviewer will then instruct the participant to grasp the handles or sides of the seat and extend their legs leaving just a slight bend in the knee. Next, the participant will remove the racking mechanism from the platform and grasp the handles or seat again. The participant will begin with a selected weight that is within their perceived ability, approximately 60 to 80% of maximum capacity (make an educated guess). The participant will lower the platform slowly and controlled towards the chest, keeping the hips and buttocks on the seat, and the back flat against the back pad. Once the thighs are parallel to the platform the participant will extend the legs, pushing the weight back to the start position as hard and as fast as possible. The participant will be instructed to not allow their hips to shift to one side, the buttocks to rise, or knees to move inward or outward during this exercise. The interviewer will also instruct the participant to keep heels flat and not allow the knees to go beyond the toes. Once the repetitions are completed, the participant will replace the racking mechanism and exit the leg press. These procedures were adapted from procedures described by the National Strength and Condition Association (2008) and the American College of Sports Medicine (2013).

Hand grip strength (MVIC; maximum voluntary isometric contraction). Hand grip strength will be measured using an isometric dynamometer (JAMAR®, Sammons, Bolingbrook, IL). The grip width will be adjusted to hand size and with arm flexed at 90°, the participant will perform three X 5 s efforts with a one min rest between trials.

Knee extension (MVIC;maximum voluntary isometric contraction). Isometric knee extension will be measured by mechanical dynamometry (Biodex System 3, Biodex Medical Systems, Shirley, NY). Participants will be positioned into the machine with the knee flexed at 90° and perform three X 5s maximal voluntary contractions with 30s rest between each trial.

Questionnaires. The RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. The Get Active Questionnaire by CSEP is a 2-page, self-administered, pre-participation for exercise screening tool. Potential participants must answer 'no' to all questions on the Get Active Questionnaire.

Being tested
Active Supplement, Placebo supplement
Medical subject headings
Overweight, Obesity, Multiple Endocrine Neoplasia Type 1

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Active SupplementDietary supplement

    Examine the effects of a multi-faceted supplement comprised of vitamins, minerals and naturally occurring and plant extracts approved for consumption of in overweight/obese men and women

  • Placebo supplementDietary supplement

    Examine the effects of a placebo supplement in overweight/obese men and women, compare to the active supplement

Study groups in NCT03812211
Study groupRoleWhat they receive
Active SupplementActive comparatorParticipants will be allocated in a randomized, double-masked manner to receive a multi-faceted supplement for the 12-week duration of the study
Receives: Dietary Supplement: Active Supplement
PlaceboPlacebo comparatorParticipants will be allocated in a randomized, double-masked manner to receive a placebo supplement (the placebo will be made of microcrystalline cellulose, and will be matched in size, appearance, taste and caloric value) for the 12-week duration of the study
Receives: Dietary Supplement: Placebo supplement

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Body composition

    Fat free mass and fat mass measured via DXA

    Measured: 12 weeks

  2. Body mass index

    Measure of body fat based on height and weight that applies to adult men and women

    Measured: 12 weeks

Secondary outcomes (9)
  1. Blood pressure

    systolic and diastolic pressure, measured in mm Hg

    Measured: 12 weeks

  2. Muscle strength

    Leg strength measured via Biodex

    Measured: 12 weeks

  3. Aerobic fitness

    VO2peak in mL/min/kg-1

    Measured: 12 weeks

  4. Fuel source utilization

    Consumed O2 compared to expired CO2

    Measured: 12 weeks

  5. Hemaglobin A1C in mmol/mol

    Amount of glycated hemoglobin

    Measured: 12 weeks

  6. Concentration of insulin in the blood

    Measures the amount of insulin in the blood.

    Measured: 12 weeks

  7. Concentration of lipids in the blood

    Cholesterol, low density lipoprotein, high density lipoprotein, triglycerides in the blood

    Measured: 12 weeks

  8. Quality of Life rating

    RAND SF(short form health survey)-36 Questionnaire; The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability

    Measured: 12 weeks

  9. Anthropometric measurements

    Waist-to-hip ratio measurements (in cm)

    Measured: 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2019
  2. Study start1 Mar 2019
  3. Primary completion24 Apr 2020
  4. Study completion2 Dec 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
65 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03812211
Sponsor's protocol ID
5754
Status last verified
Oct 2023
First submitted
18 Jan 2019
Last updated
19 Oct 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Godard MP, Johnson BA, Richmond SR. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obes Res. 2005 Aug;13(8):1335-43. doi: 10.1038/oby.2005.162.

    PubMed 16129715
  • Bailey SJ, Winyard P, Vanhatalo A, Blackwell JR, Dimenna FJ, Wilkerson DP, Tarr J, Benjamin N, Jones AM. Dietary nitrate supplementation reduces the O2 cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans. J Appl Physiol (1985). 2009 Oct;107(4):1144-55. doi: 10.1152/japplphysiol.00722.2009. Epub 2009 Aug 6.

    PubMed 19661447
  • Cordero MD, Cano-Garcia FJ, Alcocer-Gomez E, De Miguel M, Sanchez-Alcazar JA. Oxidative stress correlates with headache symptoms in fibromyalgia: coenzyme Q(1)(0) effect on clinical improvement. PLoS One. 2012;7(4):e35677. doi: 10.1371/journal.pone.0035677. Epub 2012 Apr 19.

    PubMed 22532869
  • Maki KC, Reeves MS, Farmer M, Yasunaga K, Matsuo N, Katsuragi Y, Komikado M, Tokimitsu I, Wilder D, Jones F, Blumberg JB, Cartwright Y. Green tea catechin consumption enhances exercise-induced abdominal fat loss in overweight and obese adults. J Nutr. 2009 Feb;139(2):264-70. doi: 10.3945/jn.108.098293. Epub 2008 Dec 11.

    PubMed 19074207
  • Rasool AH, Yuen KH, Yusoff K, Wong AR, Rahman AR. Dose dependent elevation of plasma tocotrienol levels and its effect on arterial compliance, plasma total antioxidant status, and lipid profile in healthy humans supplemented with tocotrienol rich vitamin E. J Nutr Sci Vitaminol (Tokyo). 2006 Dec;52(6):473-8. doi: 10.3177/jnsv.52.473.

    PubMed 17330512
  • Thom E. The effect of chlorogenic acid enriched coffee on glucose absorption in healthy volunteers and its effect on body mass when used long-term in overweight and obese people. J Int Med Res. 2007 Nov-Dec;35(6):900-8. doi: 10.1177/147323000703500620.

    PubMed 18035001
  • Zembron-Lacny A, Slowinska-Lisowska M, Szygula Z, Witkowski K, Stefaniak T, Dziubek W. Assessment of the antioxidant effectiveness of alpha-lipoic acid in healthy men exposed to muscle-damaging exercise. J Physiol Pharmacol. 2009 Jun;60(2):139-43.

    PubMed 19617657

Questions about this trial

What is this clinical trial studying?

A study testing Active Supplement in people with Overweight and Obesity and Men, run by McMaster University at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 Oct 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Body composition (time frame: 12 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03812211, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Oct 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in